Efficacy of succimer chelation for reducing brain lead in a primate model of human lead exposure

Toxicology and Applied Pharmacology

Volumn 161, Issue 3, 1999, Pages 283-293

  Cremin Jr , J D ^a   Luck, M L ^b   Laughlin, N K ^b   Smith, D R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Brain; Chelation; Lead; Nonhuman primate; Succimer

Indexed keywords

LEAD; SUCCIMER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN BIOPSY; CHELATION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; LEAD POISONING; MALE; NEUROTOXICITY; NONHUMAN; PREFRONTAL CORTEX; RHESUS MONKEY;

ANIMALIA; MACACA MULATTA; PRIMATES;

EID: 0033572831     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1999.8807     Document Type: Article

References (51)

1. Aposhian H. V., Aposhian M. M. Meso-2,3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu. Rev. Pharmacol. Toxicol. 30:1990;279-306.
2. Aschengrau A., Beiser A., Bellinger D., Copenhafer D., Weitzman M. The impact of soil lead abatement on urban children's blood lead levels: phase II results from the Boston Lead-In-Soil Demonstration Project. Environ. Res. 67:1994;125-148.
3. Chisolm J. J. BAL, EDTA, DMSA and DMPS in the treatment of lead poisoning in children. Clin. Toxicol. 30:1992;493-504.
4. Collins M. F., Hrdina P. D., Whittle E., Singhal R. L. Lead in blood and brain regions of rats chronically exposed to low doses of the metal. Toxicol. Appl. Pharmacol. 65:1982;314-322.
5. Cooper B. R., White H. L., Beek O., Norton R. M., Rigdon G. C., Howard J. L., Kraemer G. W., Ferris R. M. Overview of the CNS pharmacology of BW 137OU87: a chemically novel, reversible, selective MAO-A inhibitor with potential to be a new antidepressant drug. Drug. Dev. Res. 25:1992;181-190.
6. Cory-Slechta D. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. J. Pharmacol. Exp. Ther. 246:1988;84-91.
7. Cory-Slechta D. A. Relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic, and glutamatergic neurotransmitter system functions. Annu. Rev. Pharmacol. Toxicol. 35:1995;391-415.
8. Cremer J. E., Seville M. P. Regional brain blood flow, blood volume, and haematocrit values in the adult rat. J. Cereb. Blood Flow Metab. 3:1983;254-256.
9. Dart R. C., Hurlbut K. M., Maiorino R. M., Mayersohn M., Aposhian H. V., Hassen L. V. Pharmacokinetics of meso-2,3-dimercaptosuccinic acid in patients with lead poisoning and in healthy adults. J. Pediatr. 125:1994;309-316.
10. Finkelstein Y., Markowitz M. E., Rosen J. F. Low-level lead-induced neurotoxicity in children: an update on central nervous system effects. Brain Res. Rev. 27:1998;168-176.
11. Flora S. J., Bhattacharya R., Vijayaraghavan R. Combined therapeutic potential of meso-2,3-dimercaptosuccinic acid and calcium disodium edetate on the mobilization and distribution of lead in experimental lead intoxication in rats. Fundam. Appl. Toxicol. 25:1995;233-240.
12. Glotzer D. E. The current role of 2,3-dimercaptosuccinic acid (DMSA) in the management of childhood lead poisoning. Drug Safety. 9:1993;85-92.
13. Goldstein G., Asbury A., Diamond I. Pathogenesis of lead encephalopathy. Arch. Neurol. 31:1974;382-389.
14. Graziano J. H. Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med. Toxicol. 1:1986;155-162.
15. Graziano J. H., Lolacono N. J., Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J. Pediatr. 113:1988;751-757.
16. Graziano J. H., Lolacono N. J., Moulton T., Mitchell M. E., Slavkovich V., Zarate C. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J. Pediatr. 120:1992;133-139.
17. Graziano J. H., Siris E. S., LoIacono N., Silverberg S. J., Turgeon L. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clin. Pharmacol. Ther. 37:1985;431-438.
18. Jones M., Basinger M., Gale G., Atkins L., Smith A., Stone A. Effect of chelate treatments on kidney, bone, and brain lead levels of lead-intoxicated mice. Toxicology. 89:1994;91-100.
19. Kraemer G. W., Clark A. S. The behavioral neurobiology of self-injurious behavior in rhesus monkeys. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 14:1990;S141-S158.
20. Kraemer G. W., Ebert M. H., Schmidt D. E., McKinney W. T. A longitudinal study of the effect of different social rearing conditions on cerebrospinal fluid norepinephrine and biogenic amine metabolites in rhesus monkeys. Neuropsychopharmacology. 2:1989;175-189.
21. Kraemer G. W., Schmidt D. E., Ebert M. H. The behavioral neurobiology of self-injurious behavior in rhesus monkeys: current concepts and relations to impulsive behavior in humans. Ann. N. Y. Acad. Sci. 836:1997;12-38.
22. Laughlin N. K., Lasky R. E., Giles N. L., Luck M. L. Lead effects on development in the neonatal rhesus monkey (Macaca mulatta). Neurotoxicol. Teratol. 1999.
23. Leggett R. W. An age-specific kinetic model of lead metabolism in humans. Environ. Health Perspect. 101:1993;598-616.
24. 2 in the mouse after intravenous injection. Neurotoxicology. 19:1998;197-208.
25. Liebelt E. L., Shannon M., Graef J. W. Efficacy of oral meso-2,3-dimercaptosuccinic acid therapy for low-level childhood plumbism. J. Pediatr. 124:1994;313-317.
26. McGown E. L., Tillotson J. A., Knudsen J. J., Dumlao C. R. Biological behavior and metabolic fate of the BAL analogues DMSA and DMPS. Proc. West. Pharmacol. Soc. 27:1984;169-176.
27. Melman S. T., Nimeh J. W., Anbar R. D. Prevalence of elevated blood lead levels in an inner-city pediatric clinic population. Environ. Health Perspect. 106:1998;655-657.
28. Nawashiro H., Shima K., Chigasaki H. Blood-brain barrier, cerebral blood flow, and cerebral plasma volume immediately after head injury in the rat. Acta Neurochir. Suppl. 60:1994;440-442.
29. Needleman H. L., Riess J. A., Tobin M. J., Biesecker G. E., Greenhouse J. B. Bone lead levels and delinquent behavior. JAMA. 275:1996;363-369.
30. NRC. 1996. Guide for the Care and Use of Laboratory Animals. National Research Council, National Academy Press, Washington, DC, 1996, pp. 1-125.
31. O'Flaherty E. J., Inskip M. J., Franklin C. A., Durbin P. W., Manton W. I., Baccanale C. L. Evaluation and modification of a physiologically based model of lead kinetics using data from a sequential isotope study in cynomolgus monkeys. Toxicol. Appl. Pharmacol. 149:1998;1-16.
32. O'Flaherty E. J., Inskip M. J., Yagminas A. P., Franklin C. A. Plasma and blood lead concentrations, lead absorption, and lead excretion in nonhuman primates. Toxicol. Appl. Pharmacol. 138:1996;121-130.
33. Pappas J., Ahlquist J., Allen E., Banner W. Oral dimercaptosuccinic acid and ongoing exposure to lead: effects on heme synthesis and lead distribution in a rat model. Toxicol. Appl. Pharmacol. 133:1995;121-129.
34. Penn R. D., Walser R., Ackerman L. Cerebral blood volume in man. JAMA. 234:1975;1154-1155.
35. Pirkle J. L., Kaufmann R. B., Brody D. J., Hickman T., Gunter E. W., Paschal D. C. Exposure of the U.S. population to lead, 1991-1994. Environ. Health Perspect. 106:1998;745-750.
36. Rajan M. T., Jagannatha Rao K. S., Mamatha B. M., Rao R. V., Shanmugavelu P., Menon R. B., Pavithran M. V. Quantification of trace elements in normal human brain by inductively coupled plasma atomic emission spectrometry. J. Neurol. Sci. 146:1997;153-166.
37. Rice D. C. Lead-induced changes in learning: evidence for behavioral mechanisms from experimental animal studies. Neurotoxicology. 14:1993;167-178.
38. Rice D. C. Behavioral effects of lead: commonalities between experimental and epidemiologic data. Environ. Health Perspect. 104:1996;337-351.
39. Rodier P. M. Developing brain as a target of toxicity. Environ. Health Perspect. 103:1995;73-76.
40. Ruff H. A., Bijur P. E., Markowitz M., Yeou-Cheng M., Rosen J. F. Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA. 269:1993;1641-1646.
41. Smith D., Bayer L., Strupp B. J. Efficacy of succimer chelation for reducing brain Pb levels in a rodent model. Environ. Res. 78:1998;168-176.
42. Smith D. R., Flegal A. R. Stable isotopic tracers of lead mobilized by DMSA chelation in low lead-exposed rats. Toxicol. Appl. Pharmacol. 116:1992;85-91.
43. 204Pb. Environ. Res. 67:1994;39-57.
44. Smith D. R., Osterloh J., Niemeyer S., Flegal A. R. Stable isotope labeling of lead compartments in rats with ultra-low lead concentrations. Environ. Res. 57:1992;190-207.
45. SAS Institute1989. SAS/STAT User's Guide. Version 6, 4th ed., SAS Institute, Inc. Cary, NC.
46. TLC (The Treatment of Lead-exposed Children Trial Group). (1998). The Treatment of Lead-exposed Children (TLC) trial: design and recruitment for a study of the effect of oral chelation on growth and development in toddlers. Paediatr. Perinatal Epidemiol.12, 313-333.
47. U.S. Environmental Protection Agency (EPA) (1998), Review of Studies Addressing Lead Abatement Effectiveness., EPA 747-B-98-001, U.S. Environmental Protection Agency, Washington, DC.
48. Widzowski D. V., Cory-Slechta D. A. Homogeneity of regional brain lead concentrations. Neurotoxicology. 15:1994;295-308.
49. Woolard D., Franks R., Smith D. R. An inductively coupled plasma - magnetic sector mass spectrometry method for stable lead isotope tracer studies. J. Anal. At. Spect. 13:1998;1015-1019.
50. Xu Z.-F., Jones M. M. Comparative mobilization of lead by chelating agents. Toxicology. 53:1988;277-288.
51. Zuch C. L., O'Mara D. J., Cory-Slechta D. A. Low-level lead exposure selectively enhances dopamine overflow in nucleus accumbens: an in vivo electrochemistry time course assessment. Toxicol. Appl. Pharmacol. 150:1998;174-185.